Earnings
OnKure Reports $163.3 Million In Cash, Enough To Last Into 2029, And Launches A Vascular Registry
The biotech's third-quarter net loss was $17.8 million, and both next-generation drug candidates are on track for FDA filings in the first half of 2027.
